AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Lexaria Bioscience Corp. Director's Dealing 2024

Mar 15, 2024

34983_dirs_2024-03-15_fefa3434-7497-4e03-a95f-13d00eb83a2f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Lexaria Bioscience Corp. (LEXX)
CIK: 0001348362
Period of Report: 2024-03-14

Reporting Person: Cabatuan Nelson (Chief Financial Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options	$2.93	2029-03-15	Common Shares (200000)		Direct

Footnotes

F1: 50,000 options are exercisable on March 15, 2024, an additional 50,000 options are exercisable on March 15, 2025, thereafter an additional 4,166 options are exercisable monthly until Feb. 15, 2027 with the balance of 4,182 options being exercisable on March 15, 2027